With Blinatumomab, an anti-CD19/CD3 T Cell-Engaging Bispecific Antibody (TCEBA), approval in 2018 and the European Commission approval of Mosunetuzumab, an anti-CD20/CD3 TCEBA, in 2022, TCEBA has become a focus of antibody industry. However, whether an antibody is a good candidate for using to generate TCEBA is determined by several factors. For instance, epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by TCEBA specific for a large surface antigen.

Therefore, we provide a service to help customs to determine whether their antibodies could be a potential TCEBA. If you are interested in this service, please contact us.

Blinatumomab與 Mosunetuzumab這二種雙特異性T細胞銜接抗體 (T Cell-Engaging Bispecific Antibody)分別在2018和2022年獲得核准上市，使得雙特異性T細胞銜接抗體已是國際大藥廠和抗體產業的產品重心。但是，雙特異性T細胞銜接抗體的效能受到多種因子的影響；例如：抗體結合在抗原上的位置與標的細胞的細胞膜的距離是影響雙特異性T細胞銜接抗體效能的主要因素。

因此，我們提供一個服務來協助客戶判斷客戶手中的抗體是否適合發展成雙特異性T細胞銜接抗體。如果你對此服務有需求，請與我們聯繫。